Patient and disease characteristics, by cytogenetic risk status
| Characteristic . | Favorable (n = 121) . | Intermediate (n = 278) . | Unfavorable (n = 184) . | Unknown (n = 26) . |
|---|---|---|---|---|
| Age, y | ||||
| Median | 34 | 40 | 39 | 44 |
| Range | 17-54 | 16-55 | 17-54 | 18-54 |
| Female | 43% | 54% | 40% | 35% |
| Median WBC (× 109/L) | 15.1 | 18.0 | 9.5 | 21.5 |
| Median marrow blast3-150 | 56% | 64% | 69% | 83% |
| Median blood blast3-150 | 38% | 37% | 30% | 52% |
| Median hemoglobin (g/dL)3-150 | 8.7 | 9.3 | 8.7 | 9.0 |
| Median platelets (× 109/L)3-150 | 37 | 61 | 56 | 41 |
| Hepatomegaly3-150 | 8% | 8% | 6% | 0% |
| Splenomegaly3-150 | 9% | 9% | 10% | 4% |
| Extramedullary leukemia3-150 | 42% | 49% | 44% | 41% |
| Fever > 38° at presentation3-150 | 47% | 44% | 51% | 26% |
| Zubrod performance status3-150 | ||||
| 0 | 36% | 33% | 38% | 35% |
| 1 | 51% | 54% | 43% | 46% |
| 2-4 | 12% | 13% | 18% | 19% |
| Fab class (central morphology review) | ||||
| M1 | 7% | 27% | 21% | 31% |
| M2 | 42% | 27% | 27% | 31% |
| M33-151 | 17% | 3% | 1% | 8% |
| M4 | 21% | 14% | 10% | 0% |
| M5 | 1% | 12% | 11% | 12% |
| M6 | 0% | 3% | 5% | 0% |
| Other3-152 | 3% | 8% | 18% | 15% |
| Unknown3-153 | 9% | 7% | 7% | 4% |
| Characteristic . | Favorable (n = 121) . | Intermediate (n = 278) . | Unfavorable (n = 184) . | Unknown (n = 26) . |
|---|---|---|---|---|
| Age, y | ||||
| Median | 34 | 40 | 39 | 44 |
| Range | 17-54 | 16-55 | 17-54 | 18-54 |
| Female | 43% | 54% | 40% | 35% |
| Median WBC (× 109/L) | 15.1 | 18.0 | 9.5 | 21.5 |
| Median marrow blast3-150 | 56% | 64% | 69% | 83% |
| Median blood blast3-150 | 38% | 37% | 30% | 52% |
| Median hemoglobin (g/dL)3-150 | 8.7 | 9.3 | 8.7 | 9.0 |
| Median platelets (× 109/L)3-150 | 37 | 61 | 56 | 41 |
| Hepatomegaly3-150 | 8% | 8% | 6% | 0% |
| Splenomegaly3-150 | 9% | 9% | 10% | 4% |
| Extramedullary leukemia3-150 | 42% | 49% | 44% | 41% |
| Fever > 38° at presentation3-150 | 47% | 44% | 51% | 26% |
| Zubrod performance status3-150 | ||||
| 0 | 36% | 33% | 38% | 35% |
| 1 | 51% | 54% | 43% | 46% |
| 2-4 | 12% | 13% | 18% | 19% |
| Fab class (central morphology review) | ||||
| M1 | 7% | 27% | 21% | 31% |
| M2 | 42% | 27% | 27% | 31% |
| M33-151 | 17% | 3% | 1% | 8% |
| M4 | 21% | 14% | 10% | 0% |
| M5 | 1% | 12% | 11% | 12% |
| M6 | 0% | 3% | 5% | 0% |
| Other3-152 | 3% | 8% | 18% | 15% |
| Unknown3-153 | 9% | 7% | 7% | 4% |
Results are based on fewer than 609 patients with data available.
Of 33 morphologic M3 cases, all 21 with t(15;17) were coded as favorable; 9 karyotypically normal cases were coded as intermediate; one 11q23 case was coded as unfavorable [t(11;17)(q2?3;q2?5)]; and 2 were coded as unknown [add(1)(q22) and add(13)(q1?4)].
Other includes M0, M7, AML (not otherwise specified), and miscellaneous other.
Patients with no or inadequate materials submitted for central morphology review.